These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37544137)

  • 1. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors.
    Pierce JB; Blumer V; Choi S; Hardy NC; Greiner MA; Carnicelli AP; Shen X; Lippmann SJ; Peterson PN; Allen LA; Fonarow GC; Mentz RJ; Greene SJ; O'Brien EC
    Am J Cardiol; 2023 Oct; 204():151-158. PubMed ID: 37544137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Carnicelli AP; Li Z; Greiner MA; Lippmann SJ; Greene SJ; Mentz RJ; Hardy NC; Blumer V; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
    JACC Heart Fail; 2021 Dec; 9(12):876-886. PubMed ID: 34509408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.
    Bhatt AS; Vaduganathan M; Solomon SD; Schneeweiss S; Lauffenburger JC; Desai RJ
    Eur J Heart Fail; 2022 Sep; 24(9):1506-1515. PubMed ID: 35689603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
    Carnicelli AP; Lippmann SJ; Greene SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
    J Card Fail; 2021 Aug; 27(8):826-836. PubMed ID: 34364659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril-Valsartan in Patients Requiring Hemodialysis.
    Le D; Grams ME; Coresh J; Shin JI
    JAMA Netw Open; 2024 Aug; 7(8):e2429237. PubMed ID: 39163041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care.
    Bhatt AS; Vaduganathan M; Zhuo M; Fu EL; Solomon SD; Desai RJ
    J Card Fail; 2023 Feb; 29(2):138-146. PubMed ID: 36191759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
    Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
    Shore S; Basu T; Kamdar N; Brady P; Birati E; Hummel SL; Chopra V; Nallamothu BK
    J Am Heart Assoc; 2022 Sep; 11(17):e023950. PubMed ID: 36000415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
    He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
    Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
    Gilstrap L; Zipkin RJ; Barnes JA; King A; O'Malley AJ; Gaziano TA; Tosteson ANA
    Am Heart J; 2022 Aug; 250():23-28. PubMed ID: 35525261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.